Phase 2 Endometriosis Trial, Recruiting NCT07260669 Sponsor: Gesynta Pharma AB Condition: Endometriosis
Back to Endometriosis

Phase 2 Endometriosis Trial, Recruiting

NCT07260669
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are a woman who has not yet gone through menopause and are between 18 and 44 years old at your first visit
  • You have been diagnosed with endometriosis within the last 10 years (or at your first visit), confirmed either through surgery (by a doctor directly seeing or taking a tissue sample of the affected area) or through an imaging scan such as an ultrasound or MRI
  • You have a history of ongoing pelvic pain outside of your period that significantly affects your daily life, confirmed at your first visit
  • In the month before your second visit, you report experiencing moderate, severe, or very severe pain on days when you do not have your period

Who may not be able to join:

  • You have long-term pelvic pain that doctors believe is mainly caused by something other than endometriosis, such as a chronic pelvic infection, bladder condition, nerve problems, pelvic scarring unrelated to endometriosis, certain types of ovarian cysts, complications from a tubal ligation, fluid-filled fallopian tubes, or muscle spasm-related pain (confirm with trial site)
  • You have already had more than 2 surgeries specifically to treat endometriosis

⚠️ Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +46 762 788 389

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Gesynta Pharma AB
Registry
ClinicalTrials.gov
Start date
15 October 2025
Est. completion
1 June 2027

Where this trial is recruiting

🇧🇬 Bulgaria 🇨🇿 Czechia 🇭🇺 Hungary 🇮🇹 Italy 🇵🇱 Poland 🇷🇴 Romania 🇬🇧 United Kingdom

Primary endpoints

Percentage of Participants who meet the Predefined NMPP Responder Criteria from Baseline to Fourth Month of Treatment

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov